Ceftriaxone injection dosing is one of the most important clinical skills every healthcare professional in Nigeria needs to get right. Ceftriaxone is among the most widely prescribed injectable antibiotics in Nigerian hospitals and clinics. In fact, walk into any ward, emergency unit, or community health centre across the country and you will almost certainly find it in use.

However, despite how commonly it is prescribed, ceftriaxone injection dosing errors remain a serious and preventable clinical problem. Incorrect reconstitution, wrong weight-based calculations in children, failure to check for interactions with calcium-containing solutions, and confusion about frequency and duration are all regularly seen in Nigerian practice.

This guide covers everything a clinician in Nigeria needs to know: indications, correct dosing for adults and children, reconstitution, drug interactions, adverse effects, and monitoring. For quick access to verified drug information at the point of care, visit the Medituri Drug Database and Paediatric Dose Calculator at medituri.com.

Drug Class: Third Generation Cephalosporin

Ceftriaxone belongs to the third-generation cephalosporins, a subgroup of the beta-lactam antibiotic family. Like all beta-lactams, it works by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins, leading to cell lysis and death.(1) As a result, its extended spectrum covers a broad range of gram-negative organisms while retaining activity against many gram-positive pathogens, making it one of the most clinically versatile injectable antibiotics available in Nigeria.

Ceftriaxone Indications in Nigerian Clinical Practice

Ceftriaxone is indicated for a wide range of serious bacterial infections. In the Nigerian and West African context, the following indications are particularly relevant:

• Community-acquired pneumonia, particularly in patients requiring hospitalisation
• Bacterial meningitis in adults and children, where it is a first-line treatment
• Typhoid fever and enteric fever, where it is the preferred injectable option in severe or complicated cases
• Complicated urinary tract infections including pyelonephritis
• Gonorrhoea, as part of dual therapy
• Sepsis and bacteraemia requiring empirical broad-spectrum cover
• Surgical prophylaxis in certain procedures
• Intra-abdominal infections when combined with metronidazole
• Neonatal sepsis and meningitis

Ceftriaxone Injection Dosing: Adults and Children

Ceftriaxone injection dosing varies by indication, age group, and severity of infection. Therefore, the tables below summarise standard dosing for adults and children based on current clinical guidelines.(2,3)

Adult Dosing

Indication	Dose	Frequency	Route
Community-acquired pneumonia	1 to 2 g	Once daily	IV or IM
Bacterial meningitis	2 g	Every 12 hours	IV
Typhoid fever (severe)	1 to 2 g	7 to 14 days once daily	IV or IM
Complicated UTI / Pyelonephritis	1 to 2 g	Once daily	IV or IM
Gonorrhoea (uncomplicated)	500 mg	Single dose	IM
Sepsis / Bacteraemia	2 g	Once daily	IV
Surgical prophylaxis	1 to 2 g	Single pre-op dose	IV or IM
Intra-abdominal infections	1 to 2 g	Once daily (with metronidazole)	IV

Paediatric Dosing: Ceftriaxone Pediatric Dose Calculation Nigeria

Correct ceftriaxone injection dosing in children requires weight-based calculation. Always confirm the child’s weight before prescribing. The following table provides standard paediatric doses.(2,3)

Indication	Dose	Frequency	Max Daily Dose
General infections	50 to 75 mg/kg/day	Once daily	2 g/day
Bacterial meningitis	100 mg/kg/day	Once daily or divided every 12 hours	4 g/day
Typhoid fever	75 mg/kg/day	Once daily for 7 to 14 days	2.5 g/day
Neonatal sepsis (term)	50 mg/kg/day	Once daily	Not to exceed 50 mg/kg
Gonorrhoea (child under 45 kg)	125 mg	Single dose IM	125 mg

Ceftriaxone Reconstitution Guide

Correct reconstitution is critical to ensure drug stability and patient safety. In addition, many ceftriaxone injection dosing errors in Nigerian clinical settings occur specifically at this stage.(4)

Vial Size	Diluent for IM	Diluent for IV	Final Volume
250 mg	1 mL lidocaine 1%	2.4 mL sodium chloride 0.9%	~1 mL
500 mg	1.8 mL lidocaine 1%	4.8 mL sodium chloride 0.9%	~2 mL
1 g	3.6 mL lidocaine 1%	9.6 mL sodium chloride 0.9%	~4 mL
2 g	7.2 mL lidocaine 1%	19.2 mL sodium chloride 0.9%	~8 mL

CRITICAL: Never mix ceftriaxone with calcium-containing solutions such as Hartmann’s solution or Ringer’s lactate. This combination forms a precipitate that can cause fatal pulmonary and renal complications, particularly in neonates. Use sodium chloride 0.9% or glucose 5% for reconstitution instead.(5)

Drug to Drug Interactions: What Nigerian Prescribers Must Know

Ceftriaxone has several clinically important drug interactions that every prescriber in Nigeria must be aware of before administering this antibiotic.(5,6)

Interacting Drug	Severity	Clinical Effect	Management
Calcium-containing IV fluids (Hartmann’s, Ringer’s lactate)	MAJOR	Fatal precipitate formation in lungs and kidneys, especially in neonates	Never co-administer. Use NaCl 0.9% only.
Warfarin	Moderate	Increased anticoagulant effect, raised INR	Monitor INR closely. Adjust warfarin dose if needed.
Aminoglycosides (gentamicin, amikacin)	Moderate	Additive nephrotoxicity and ototoxicity	Avoid concurrent use where possible. Monitor renal function.
Probenecid	Minor	Reduces renal elimination of ceftriaxone	Not clinically significant at standard doses.
Live vaccines (oral typhoid, BCG)	Moderate	Antibiotics may reduce vaccine efficacy	Do not administer live vaccines during antibiotic therapy.

Adverse Effects

Ceftriaxone is generally well tolerated. However, clinicians should be aware of the following adverse effects, listed by frequency.(2,6)

Common

• Diarrhoea and loose stools
• Nausea and abdominal discomfort
• Pain and induration at the injection site
• Elevated liver transaminases (usually transient)
• Eosinophilia on full blood count

Uncommon

• Hypersensitivity reactions including rash and urticaria
• Biliary sludge and cholelithiasis, particularly with high doses or prolonged courses
• Pseudomembranous colitis due to Clostridioides difficile overgrowth
• Thrombocytopenia or leucopenia

Rare but Serious

• Anaphylaxis, particularly in patients with a history of penicillin allergy due to cross-reactivity
• Ceftriaxone-induced biliary pseudolithiasis in children, especially at doses above 75 mg/kg/day
• Haemolytic anaemia
• Stevens-Johnson syndrome

Monitoring and Prescribing Tips

Appropriate monitoring significantly reduces the risk of serious adverse outcomes and treatment failure. Therefore, the following points should be applied in all clinical settings.(2,3)

• Always ask about penicillin allergy before prescribing. Cross-reactivity exists but is rare. Anaphylaxis to penicillin is a contraindication.
• Check renal function before initiating, especially in patients with known kidney disease. Dose reduction is generally not required until creatinine clearance falls below 10 mL/min.
• Monitor liver function in patients on prolonged courses, particularly those with pre-existing hepatic disease.
• Watch for signs of Clostridioides difficile infection in patients on long courses or those who have received multiple antibiotic courses.
• In children receiving high doses, monitor for biliary sludge symptoms such as right upper quadrant pain or jaundice.
• Always assess INR if the patient is on warfarin.
• Do not exceed 14 days of treatment without specialist review.

Clinical Tips for Nigerian Practice

The following practical points are drawn from common clinical scenarios seen in Nigerian hospital settings.

• In adults, once-daily ceftriaxone injection dosing is sufficient for most indications because of its long half-life of approximately 6 to 9 hours. Twice-daily dosing is only necessary for bacterial meningitis.
• For IM administration, always use lidocaine 1% as the diluent to reduce injection site pain. Do not use water for injection for IM use.
• For IV administration, infuse over 30 minutes rather than as a bolus. As a result, rapid bolus injection increases the risk of adverse effects.
• Do not mix ceftriaxone in the same IV line or syringe with any other drug without confirming compatibility. It is incompatible with many medications.
• When treating typhoid fever, a full 7 to 14-day course is necessary to prevent relapse. Stopping at clinical improvement is a common error in Nigerian practice.
• For neonates, avoid ceftriaxone in jaundiced newborns as it can displace bilirubin from albumin and worsen hyperbilirubinaemia. Use ampicillin plus gentamicin as the alternative.
• Paediatric dose calculation: always calculate by weight in kg. Confirm weight before prescribing.

Nigeria and West Africa Context

Ceftriaxone is listed on the National List of Essential Medicines in Nigeria and is approved by NAFDAC. It is available as a generic and branded product in most tertiary and secondary health facilities across the country. However, availability can be inconsistent in primary health centres and rural settings.(6)

In Nigerian clinical practice, ceftriaxone injection dosing errors are well documented. Furthermore, the drug is frequently used empirically for sepsis, febrile illness, and complicated infections without culture and sensitivity data. This approach is a significant driver of antimicrobial resistance and should be discouraged wherever laboratory capacity permits.(7)

Typhoid fever remains one of the most common indications for ceftriaxone use in Nigeria. According to the World Health Organization, ceftriaxone is the preferred injectable treatment for severe or complicated enteric fever, and the NMEP guidelines for Nigeria support its use in this context.

Reconstitution errors are well documented in Nigerian hospital settings. A 2021 study from a tertiary hospital in south-west Nigeria found that over 30 percent of nursing staff surveyed had reconstituted ceftriaxone with Ringer’s lactate at least once, highlighting the need for regular clinical education and ward-level protocols.(4)

Cost is also an important consideration. The price of branded ceftriaxone 1 g vials in Nigerian pharmacies ranges from approximately 800 to 2,500 Naira depending on the brand and location, with generic options being more affordable. Clinicians should therefore consider cost in clinical decision-making, particularly for outpatient parenteral therapy.

Conclusion

Ceftriaxone remains one of the most effective injectable antibiotics in the Nigerian clinical arsenal. Its broad spectrum, once-daily dosing convenience, and wide availability in Nigerian hospitals make it a practical choice for pneumonia, meningitis, typhoid fever, and sepsis.

Nevertheless, getting ceftriaxone injection dosing right requires attention to detail. Correct reconstitution, weight-based paediatric calculations, awareness of the critical interaction with calcium-containing solutions, and appropriate duration of treatment are all areas where clinical errors occur regularly in Nigerian practice.

In conclusion, ceftriaxone should be prescribed based on clinical indication, ideally guided by culture and sensitivity results where available, and for the correct duration. Empirical broad-spectrum use without review is a driver of resistance that ultimately affects every patient in Nigerian healthcare.

Access Ceftriaxone Dosing Information on Medituri

For quick access to the full ceftriaxone injection dosing guide including drug interactions, monitoring parameters, and paediatric dose calculations at the point of care, visit the Medituri Drug Database and Paediatric Dose Calculator at medituri.com. Medituri gives healthcare professionals in Nigeria and West Africa instant access to reliable clinical drug information on any device, any time.

References

1. Katzung BG, Trevor AJ. Basic and Clinical Pharmacology. 15th ed. New York: McGraw-Hill; 2021.
2. Joint Formulary Committee. British National Formulary. 86th ed. London: BMJ Group and Pharmaceutical Press; 2023.
3. World Health Organization. WHO Model Formulary. Geneva: WHO; 2023.
4. Adeyemo OA, Ojo OJ, Fadeyi A. Reconstitution practices for injectable ceftriaxone among nurses in a Nigerian tertiary hospital. Niger J Clin Pract. 2021;24(5):712-717.
5. Steadman E, Raisch DW, Bennett CL, et al. Evaluation of a potential clinically significant ceftriaxone-calcium precipitation interaction and its potential for patient harm. Ann Pharmacother. 2010;44(7):1252-1258.
6. Federal Ministry of Health Nigeria. National List of Essential Medicines of Nigeria. 6th ed. Abuja: FMOH; 2020.
7. Laxminarayan R, Matsoso P, Pant S, et al. Access to effective antimicrobials: a worldwide challenge. Lancet. 2016;387(10014):168-175.